Searched for
BIOCON DRUGS FOR CANCER
Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...05 May, 2026, 01.56 PM IST- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...05 May, 2026, 11.51 AM IST
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...27 Apr, 2026, 08.52 AM IST
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...09 Mar, 2020, 10.13 AM IST
- Biocon, Mylan launch cancer drug in US marketOgivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and met...02 Dec, 2019, 06.45 PM IST
- Biosimilar drug by Mylan, Biocon gets USFDA approvalBiosimilar drugs are identical copy of highly complex biologic drugs that claim to have the same efficacy as that off the innovator’s versi...03 Dec, 2017, 10.44 PM IST
- Biocon introduces oncologic biosimilar KRABEVA in IndiaThe biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervic...23 Nov, 2017, 01.57 PM IST
- Biocon's pain could continue post EU drug application withdrawalBiocon shares tanked 5.9 per cent to Rs 328.80 at the close on the BSE on Wednesday.17 Aug, 2017, 08.54 AM IST
- Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drugThe USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.14 Jul, 2017, 08.38 AM IST
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...04 Mar, 2017, 11.42 AM IST
- HC allows Biocon, Mylan to sell their drug for three cancersBiocon and Mylan had appealed against the single judge order as restrictions were imposed on the use of clinical data in the package insert...03 Mar, 2017, 06.03 PM IST
- Delhi HC asks government if it approved Biocon’s trastuzumab for three cancersBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...23 Feb, 2017, 06.05 AM IST
- Biocon launches breast-cancer drug CANMAbPriced at Rs 19,500 per vial, Biocon is expecting to target close to 35,000 patients with this drug.19 Jan, 2014, 04.00 AM IST
- Biocon's breast cancer drug 'CANMAb' to hit markets next monthBiotechnology major Biocon will start selling breast cancer drug 'CANMAb', developed jointly with US-based Mylan, in the country from next ...18 Jan, 2014, 08.20 PM IST
- Biocon-Mylan partnership has a potential of $33 billion from biosimilar drugsTwo years after announcing a JV with Mylan, Biocon has revealed the potential of its drugs under the biologics deal with Mylan.08 May, 2012, 11.18 AM IST
- Biocon to partner US-based firm for developing cancer drugBiotech major Biocon Ltd on Thursday said it will enter into a partnership with a US-based biotechnology company, Iatrica, to develop drug ...17 Jan, 2008, 02.46 PM IST
- World's first anti-EGFR cancer antibody launchedBiotechnology behemoth Biocon has launched BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumours of epitheli...18 Sep, 2006, 01.34 AM IST
Load More
